Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH ‐wildtype glioblastoma-Reference-Cited by-同舟云学术

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH ‐wildtype glioblastoma

Published:2021-04-10 Issue:10 Volume:10 Page:3177-3187
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Funakoshi Yusuke¹,Hata Nobuhiro¹^ORCID,Takigawa Kosuke¹,Arita Hideyuki²,Kuga Daisuke¹,Hatae Ryusuke¹,Sangatsuda Yuhei¹,Fujioka Yutaka¹,Sako Aki¹,Umehara Toru²,Yoshitake Tadamasa³,Togao Osamu³,Hiwatashi Akio³,Yoshimoto Koji¹⁴,Iwaki Toru⁵,Mizoguchi Masahiro¹

Affiliation:

1. Department of Neurosurgery Graduate School of Medical Sciences Kyushu University Fukuoka Japan

2. Department of Neurosurgery Graduate School of Medicine Osaka University Suita Japan

3. Department of Clinical Radiology Graduate School of Medical Sciences Kyushu University Fukuoka Japan

4. Department of Neurosurgery Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan

5. Department of Neuropathology Graduate School of Medical Sciences Kyushu University Fukuoka Japan

Funder

Inamori Foundation

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3860

Reference45 articles.

1. The Somatic Genomic Landscape of Glioblastoma

2. MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma

3. Repair of DNA containing O 6 ‐alkylguanine

4. The prognostic value of MGMT promoter methylation in glioblastoma: A meta‐analysis of clinical trials

5. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined inhibition of EZH2 and CDK4/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma;npj Precision Oncology;2024-07-25

2. Pervasive structural heterogeneity rewires glioblastoma chromosomes to sustain patient-specific transcriptional programs;Nature Communications;2024-05-09

3. Association of body mass index with clinical outcome of primary WHO grade 4 glioma;Frontiers in Oncology;2024-04-29

4. In‐house molecular diagnosis of diffuse glioma updating the revised WHO classification by a platform of the advanced medical care system, Senshin‐Iryo;Neuropathology;2024-03-13

5. Hemizygous deletion of cyclin-dependent kinase inhibitor 2A/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult glioma;Neuro-Oncology Advances;2024-01-01